HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldstein, D. S. Articles by Kopin, I. J. Search for Related Content PubMed PubMed Citation Articles by Goldstein, D. S. Articles by Kopin, I. J.

6-[Fluorine-18]Fluorodopamine Pharmacokinetics and Dosimetry in Humans

Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke and Radiation Safety Branch, Division of Safety, Office of the Director, National Institutes of Health, Bethesda, Maryland

Correspondence: For correspondence or reprints contact: Dr. David S. Goldstein, NINDS, NIH, Building 10 Room 5N262, Bethesda, MD 20892.

ABSTRACT

PET scanning after injection of 6-[¹⁸F]fluorodopamine visualizes tissue sympathetic innervation. Organ dosimetric estimates for 6-[¹⁸F]fluorodopamine have relied on studies of rats and dogs and on literature about the fate of other radiolabeled catecholamines. This report uses empirical clinical findings in healthy volunteers to refine and extend these estimates. Methods: Thoracic PET scanning was conducted and arterial blood and urine samples were obtained after intravenous injection of 6-[¹⁸F]fluorodopamine into 10 normal volunteers. Results: The main target organs for 6-[¹⁸F]fluorodopamine-derived radioactivity were the wall of the urinary bladder (3.3 rem for a 4-Mci dose and 3.31-hr voiding interval) and the kidneys (2.9 rem for a 4-mCi dose) due to urinary excretion of radioactive metabolites of [¹⁸F]-6F-DA. The estimates were about one-fourth those predicted from studies of laboratory animals. Conclusions: At administered doses required to visualize the left ventricular myocardium in humans, a 6-[¹⁸F]fluorodopamine injection produces acceptable absorbed radiation doses, with the highest doses to the urinary collecting system.

Key Words: 6-[fluorine-18]fluorodopamine • sympathetic innervation • dosimetry • norepinephrine

This article has been cited by other articles:

				M. Hadi, C. C. Chen, M. Whatley, K. Pacak, and J. A. Carrasquillo Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma J. Nucl. Med., July 1, 2007; 48(7): 1077 - 1083. [Abstract] [Full Text] [PDF]

				D. R. Sprague, F. T. Chin, J.-S. Liow, M. Fujita, H. D. Burns, R. Hargreaves, J. B. Stubbs, V. W. Pike, R. B. Innis, and P. D. Mozley Human Biodistribution and Radiation Dosimetry of the Tachykinin NK1 Antagonist Radioligand [18F]SPA-RQ: Comparison of Thin-Slice, Bisected, and 2-Dimensional Planar Image Analysis J. Nucl. Med., January 1, 2007; 48(1): 100 - 107. [Abstract] [Full Text] [PDF]

				I. Ilias and K. Pacak Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 479 - 491. [Full Text] [PDF]

				C. J. Tack, P. J. van Gurp, C. Holmes, and D. S. Goldstein Local Sympathetic Denervation in Painful Diabetic Neuropathy Diabetes, December 1, 2002; 51(12): 3545 - 3553. [Abstract] [Full Text] [PDF]